Form 4: GeneDx CFO Sells Shares Under 10b5-1 Plan

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, exercised stock options and sold a significant number of Class A Common Stock shares pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), executed transactions involving the company's Class A Common Stock on September 30, 2025.
• These transactions were conducted under a Rule 10b5-1 trading plan, which was adopted on August 21, 2024.
• Feeley exercised employee stock options to acquire 1,246 shares of Class A Common Stock at an exercise price of $32.67 per share.
• Subsequently, he sold a total of 6,609 shares of Class A Common Stock in multiple transactions at weighted average prices ranging from $105.2412 to $113.68 per share.
• Following these reported transactions, Feeley directly beneficially owns 3,392 shares of Class A Common Stock.
• Additionally, Feeley beneficially owns restricted stock units (RSUs) representing contingent rights to receive up to an aggregate of 124,633 shares of Class A Common Stock and options to purchase up to an aggregate of 25,906 shares of Class A Common Stock, which vest according to their respective terms.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions by the CFO, including exercising options and selling shares under a pre-arranged 10b5-1 plan. While insider selling can sometimes be viewed negatively, the pre-planned nature and the significant gains realized by the officer make the overall sentiment neutral from an investment perspective, as it doesn't necessarily signal a change in company fundamentals.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned monetization strategy rather than an immediate reaction to new, undisclosed information.
• The sales occurred at significantly higher prices (ranging from $105.2412 to $113.68) compared to the option exercise price ($32.67), indicating a substantial gain for the CFO.

Negatives

• Significant insider selling, even if pre-planned, can sometimes be interpreted by the market as a lack of confidence in future stock price appreciation, especially when the volume is substantial relative to the insider's overall holdings.

Future Outlook

NA

Management Comments

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which was adopted on August 21, 2024.

Industry Context

NA

Stakeholder Impact

• Shareholders: May observe insider selling, which could be interpreted differently depending on individual investment strategies, though the 10b5-1 plan suggests a pre-determined financial management strategy by the officer.
• Employees: The vesting schedule for options and RSUs indicates ongoing equity incentives for management, aligning interests with long-term company performance.

Next Steps

• Remaining RSUs and options will vest according to their respective terms, subject to the reporting person's continued service to the Issuer.

Key Dates

Recommendation

The filing details routine insider transactions by the CFO, including exercising options and selling shares under a pre-arranged 10b5-1 plan. While the insider realized significant gains from the sales, this type of transaction is a common personal financial management strategy and does not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this disclosure. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

GeneDx Holdings Corp., WGS, Insider Trading, Form 4, Kevin Feeley, CFO, Stock Options, Share Sale, 10b5-1 Plan, Class A Common Stock